Rhythm Biosciences (ASX:RHY) Net Margin %: -4,906.52% (As of Dec. 2025)


What is Rhythm Biosciences Net Margin %?

Rhythm Biosciences ASX:RHY +1.08% Net Margin % is -4,906.52% as of Dec. 2025. The stock has 6 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Rhythm Biosciences ranks worse than 98.04% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Rhythm Biosciences's Net Income for the six months ended in Dec. 2025 was A$-2.26 Mil. Rhythm Biosciences's Revenue for the six months ended in Dec. 2025 was A$0.05 Mil. Therefore, Rhythm Biosciences's net margin for the quarter that ended in Dec. 2025 was -4,906.52%.

The historical rank and industry rank for Rhythm Biosciences's Net Margin % or its related term are showing as below:

ASX:RHY' s Net Margin % Range Over the Past 10 Years
Min: -15316   Med: -15316   Max: -14513.04
Current: -14513.04

ASX:RHY's Net Margin % is ranked worse than
98.04% of 204 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405 vs ASX:RHY: -14513.04

Rhythm Biosciences  (ASX:RHY) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Rhythm Biosciences Net Margin % Related Terms

Rhythm Biosciences Net Margin % Historical Data

* Premium members only.

The historical data trend for Rhythm Biosciences's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Biosciences Net Margin % Chart

Rhythm Biosciences Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Net Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -15,316.00

Rhythm Biosciences Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -4,906.52

ASX:RHY vs TMO, DHR, IDXX: Net Margin % Comparison

For the Diagnostics & Research subindustry, Rhythm Biosciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rhythm Biosciences Net Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's Net Margin % distribution charts can be found below:

* The bar in red indicates where Rhythm Biosciences's Net Margin % falls into.


Rhythm Biosciences Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Rhythm Biosciences's Net Margin for the fiscal year that ended in Jun. 2025 is calculated as

Net Margin=Net Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-3.829/0.025
=-15,316.00 %

Rhythm Biosciences's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-2.257/0.046
=-4,906.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -4,906.52% mean?
Rhythm Biosciences (ASX:RHY) has a Net Margin % of -4,906.52% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Rhythm Biosciences and its competitors. According to the industry distribution chart, Rhythm Biosciences ranks #200 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 98%.
Is Rhythm Biosciences' Net Margin % too high?
Rhythm Biosciences' current Net Margin % is -4,906.52%. Based on the distribution chart, Rhythm Biosciences ranks #200 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Rhythm Biosciences' Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Rhythm Biosciences ranks #200 out of 204 companies for Net Margin %. This places Rhythm Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Rhythm Biosciences and its competitors. Rhythm Biosciences's current Net Margin % is -4,906.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (ASX:RHY) has a current Net Margin % of -4,906.52%. The current Net Margin % is -4,906.52%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Rhythm Biosciences (ASX:RHY), the current Net Margin % is -4,906.52% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rhythm Biosciences Business Description

Address 30 Flemington Road, Bio21 Institute, Parkville, Melbourne, VIC, AUS, 3010
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.